news 
Windtree Therapeutics’ shares have plummeted a staggering 77% after the company received a delisting notice from Nasdaq due to non-compliance with listing rules.
On Wednesday, the biotech firm announced that it had received the delisting notification from Nasdaq, resulting in its stock price falling sharply. According to reports, Windtree’s shares plunged to $0.11 per share, marking an 85% decline from their previous value.
The news comes as a surprise to many investors and analysts, who had initially reacted positively to Windtree’s unconventional BNB treasury strategy unveiled in July. The company’s stock price soared by 32.2% following the announcement, sparking optimism about its future prospects. However, this enthusiasm was short-lived, as the delisting notice led to a sharp decline.
Windtree Therapeutics’ decision to allocate treasury funds to Binance (BNB) tokens had raised eyebrows among some investors and analysts. The move was seen as an unconventional approach, given the high volatility of cryptocurrency investments. Despite the criticism, Windtree maintained its commitment to this strategy, emphasizing the potential for long-term returns.
The delisting notice from Nasdaq has cast doubt on the future of Windtree’s BNB treasury strategy. Investors are now left wondering if the company will abandon its plans or continue with its original approach despite the setback.
Source: coincentral.com
